Cargando…

Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia

OBJECTIVES: This study aimed to assess the prognostic value of cortactin and HS1 genes expression in adult B-cell acute lymphoblastic leukemia. METHODS: The study included a cohort of 74 adult B-ALL patients and 76 controls. Cortactin and HS1 genes expression were quantified by real time PCR. RESULT...

Descripción completa

Detalles Bibliográficos
Autores principales: Aref, Salah, Al Agdar, Mohamed, Ramez, Ahmed, Abou Zeid, Tarek, Sabry, Mohamed, Khaled, Nada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286679/
https://www.ncbi.nlm.nih.gov/pubmed/33773540
http://dx.doi.org/10.31557/APJCP.2021.22.3.767
_version_ 1783723762534842368
author Aref, Salah
Al Agdar, Mohamed
Ramez, Ahmed
Abou Zeid, Tarek
Sabry, Mohamed
Khaled, Nada
author_facet Aref, Salah
Al Agdar, Mohamed
Ramez, Ahmed
Abou Zeid, Tarek
Sabry, Mohamed
Khaled, Nada
author_sort Aref, Salah
collection PubMed
description OBJECTIVES: This study aimed to assess the prognostic value of cortactin and HS1 genes expression in adult B-cell acute lymphoblastic leukemia. METHODS: The study included a cohort of 74 adult B-ALL patients and 76 controls. Cortactin and HS1 genes expression were quantified by real time PCR. RESULTS: The expression of cortactin and HS1 were significantly higher in B-ALL patients at diagnosis as compared to post induction levels (P<0.001) as well as normal controls (P<0.001 for all). Cox regression analysis revealed that B-ALL patients with high Cortactin expression as well as high HS1 expression had significant high risk of relapse (P=0.005; Odds ratio (OR)= 1.428, CI= [1.175-1.783]; and P=0.003; OR= 1.078, CI= [1.025-1.134]; respectively) and higher probability of deaths (P= 0.041; OR=1.092, CI =[1.002-1.04]; and P=0.005; OR=1.071, CI=[1.013-1,041]; respectively). Survival analysis revealed that B-ALL patients with high cortactin and high HS1 expression had significantly shorter OS and increased frequency of relapse as compared to those with lower expression levels (P <0.01 for all). CONCLUSION: High cortactin and HS1 genes expression at diagnosis denote bad clinical outcome in B-ALL patients. Assessment of correction expression at B-ALL diagnosis could be considered as risk biomarker at diagnosis.
format Online
Article
Text
id pubmed-8286679
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-82866792021-07-23 Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia Aref, Salah Al Agdar, Mohamed Ramez, Ahmed Abou Zeid, Tarek Sabry, Mohamed Khaled, Nada Asian Pac J Cancer Prev Research Article OBJECTIVES: This study aimed to assess the prognostic value of cortactin and HS1 genes expression in adult B-cell acute lymphoblastic leukemia. METHODS: The study included a cohort of 74 adult B-ALL patients and 76 controls. Cortactin and HS1 genes expression were quantified by real time PCR. RESULTS: The expression of cortactin and HS1 were significantly higher in B-ALL patients at diagnosis as compared to post induction levels (P<0.001) as well as normal controls (P<0.001 for all). Cox regression analysis revealed that B-ALL patients with high Cortactin expression as well as high HS1 expression had significant high risk of relapse (P=0.005; Odds ratio (OR)= 1.428, CI= [1.175-1.783]; and P=0.003; OR= 1.078, CI= [1.025-1.134]; respectively) and higher probability of deaths (P= 0.041; OR=1.092, CI =[1.002-1.04]; and P=0.005; OR=1.071, CI=[1.013-1,041]; respectively). Survival analysis revealed that B-ALL patients with high cortactin and high HS1 expression had significantly shorter OS and increased frequency of relapse as compared to those with lower expression levels (P <0.01 for all). CONCLUSION: High cortactin and HS1 genes expression at diagnosis denote bad clinical outcome in B-ALL patients. Assessment of correction expression at B-ALL diagnosis could be considered as risk biomarker at diagnosis. West Asia Organization for Cancer Prevention 2021-03 /pmc/articles/PMC8286679/ /pubmed/33773540 http://dx.doi.org/10.31557/APJCP.2021.22.3.767 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Aref, Salah
Al Agdar, Mohamed
Ramez, Ahmed
Abou Zeid, Tarek
Sabry, Mohamed
Khaled, Nada
Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia
title Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia
title_full Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia
title_fullStr Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia
title_full_unstemmed Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia
title_short Evaluation of Cortactin and HS1 Genes Expression: New Players in Adult B-Cell Acute Lymphoblastic leukemia
title_sort evaluation of cortactin and hs1 genes expression: new players in adult b-cell acute lymphoblastic leukemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286679/
https://www.ncbi.nlm.nih.gov/pubmed/33773540
http://dx.doi.org/10.31557/APJCP.2021.22.3.767
work_keys_str_mv AT arefsalah evaluationofcortactinandhs1genesexpressionnewplayersinadultbcellacutelymphoblasticleukemia
AT alagdarmohamed evaluationofcortactinandhs1genesexpressionnewplayersinadultbcellacutelymphoblasticleukemia
AT ramezahmed evaluationofcortactinandhs1genesexpressionnewplayersinadultbcellacutelymphoblasticleukemia
AT abouzeidtarek evaluationofcortactinandhs1genesexpressionnewplayersinadultbcellacutelymphoblasticleukemia
AT sabrymohamed evaluationofcortactinandhs1genesexpressionnewplayersinadultbcellacutelymphoblasticleukemia
AT khalednada evaluationofcortactinandhs1genesexpressionnewplayersinadultbcellacutelymphoblasticleukemia